NFKB1 and neuropathy: SUM52 treatment reduced the overexpression of proinflammatory cytokines, iNOS, and pP38 MAPK and prevented the activation of the NF-κB signaling pathway, showing an attenuation of neuroinflammation induced by the neuropathy.